Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases

NCT01337440 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes Mellitus
Chronic Liver Disease

Interventions

DRUG: UDCA
DRUG: Sitagliptin

Sponsor

Kanazawa University